Rheumatoid Arthritis Clinical Trial
Official title:
Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Compare Four Dose Regimens of GLPG0634 Versus Placebo, in Combination With Methotrexate, Administered for 4 Weeks in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone
- Ninety patients suffering from active rheumatoid arthritis despite continued treatment
with methotrexate will be evaluated for improvement of disease activity when taking
GLPG0634 (4 different doses will be evaluated) or matching placebo for 4 weeks.
- During the course of the study, patients will also be examined for any side effects
that may occur, and the amount of GLPG0634 present in the blood as well as the effects
of GLPG0634 on disease- and mechanism of action-related parameters in the blood will be
determined.
Status | Completed |
Enrollment | 91 |
Est. completion date | October 2012 |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Have active RA as shown by five or more swollen joints (from the 66-joint count), five or more tender joints (from 68-joint count), and a serum CRP =1.0 mg/dL; - Have received methotrexate for 12 weeks or longer and at a stable dose of 7.5 to 25 mg/week for at least 4 weeks prior to screening and willing to continue on this regimen for the duration of the study; - If taking oral steroids, these should be at a dose =10 mg/day of prednisone or prednisone equivalent and stable for at least 4 weeks prior to screening; - If taking non-steroidal anti-inflammatory drugs (NSAIDs), these must be at a stable dose for at least 2 weeks prior to screening; - Female subjects must have a negative pregnancy test unless they are surgically sterile or have been post-menopausal for at least one year; - Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for at least 12 weeks after the last dose of study drug. - Sexually active men must agree to use a medically acceptable form of contraception during the study and continue its use for at least 3 months after the last dose of study drug; and - Able and willing to sign the informed consent prior to screening evaluations and agree to schedule of assessments. Exclusion Criteria: - Treatment with disease-modifying antirheumatic drugs (DMARDs), other than background methotrexate; - Current or previous RA treatment with a biological agent, with the exception of biologics administered in a clinical study setting more than six months prior to screening (12 months for rituximab or other B cell depleting agents); - Previous treatment at any time with a cytotoxic agent, other than methotrexate, before screening; - Previous use of the study drug GLPG0634; - Receipt of an intra-articular or parenteral corticosteroid injection within 4 weeks prior to screening; - Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the Investigator; - Positive serology for HIV1 or 2 or hepatitis B or C, or any history of hepatitis from any cause with the exception of hepatitis A; - History of any inflammatory rheumatological disorders other than RA; - History of tuberculosis (TB) infection |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Hungary | Budai Irgalamsrendi Korhaz, II. Reumatologia Osztaly | Budapest | |
Hungary | Orszagos Reumatologiai es Fizioterapias Intezet, I. Reumatologia Osztaly | Budapest | |
Hungary | Markhot Ferenc Korhaz, Reumatologiai Osztaly | Eger | |
Hungary | Pest Megyei Flor Ferenc Korhaz, Reumatologiai es Fizioterapias Osztaly | Kistarcsa | |
Moldova, Republic of | IMSP Institutel de Cardiologie | Chisinau | |
Russian Federation | State Healthcare Institution of city Moscow 'City Clinical Hospital #7' | Moscow | |
Russian Federation | State Healthcare Institution 'Ryazan Regional Cardiology Dispensary' | Ryazan | |
Russian Federation | Saint-Petersburg State Healthcare Institution 'City Hospital #26' | Saint-Petersburg | |
Russian Federation | Saint-Petersburg State Healthcare Institution 'City Mariinskiy Hospital' | Saint-Petersburg | |
Russian Federation | Municipal Clinical Healthcare Institution 'Medical-Sanitary Unit of Novoyaroslavskiy Oil Refinery' | Yaroslavl | |
Ukraine | Chernivtsi Regional Clinical Hospital | Chernivtsi | |
Ukraine | State Institution 'Institute of Urgent and Recovery Surgery n.a. V.K. Gusaka' of AMS of Ukraine | Donetsk | |
Ukraine | Communal Institution of Healthcare | Kharkiv | |
Ukraine | Institution of Therapy of AMS of Ukraine | Kharkiv | |
Ukraine | State Institution 'Institute of Microbiology and Immunology of AMS of Ukraine' | Kharkiv | |
Ukraine | State Institution 'Republican Clinical Hospital of MoH of Ukraine' | Kiev | |
Ukraine | Lutsk City Clinical Hospital | Lutsk | |
Ukraine | Vinnytsa Regional Clinical Hospital | Vinnytsa | |
Ukraine | Zaporizhzhia Regional Clinical Hospital | Zaporizhzhia |
Lead Sponsor | Collaborator |
---|---|
Galapagos NV |
Hungary, Moldova, Republic of, Russian Federation, Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The number of patients with an ACR20 score at Week 4 as a measure of efficacy | To preliminary evaluate the efficacy of GLPG0634 compared to placebo in terms of the proportion of subjects achieving an ACR20 response at Week 4 | Week 4 (end of treatment visit) | No |
Secondary | The number of patients with ACR20/50/70 response, time to response and DAS28 score at every visit as a measure of efficacy | To evaluate the efficacy of GLPG0634 compared to placebo in terms of ACR response criteria at every visit (ACR20, ACR50, ACR70), time to response, and disease status (DAS28[C-reactive protein, CRP] | From Day -1 up to end of treatment visit (week 4) | No |
Secondary | The number of patients with adverse events, abnormal lab tests, vital signs and ECG as a measure of safety and tolerability | To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of adverse events (AEs), laboratory test abnormalities, vital signs and electrocardiogram (ECG) | From screening up to 10 days after last dose | Yes |
Secondary | The plasma levels of GLPG0634 as a measure of PK | To characterize the pharmacokinetics (PK) of GLPG0634 by measuring the amount of GLPG0634 in the plasma | Week 1, week 2 and week 4 visits | No |
Secondary | The plasma levels of GLPG0634 and MTX as a measure of PK | To explore the potential interaction of GLPG0634 on MTX by assessing steady state PK in an 8-hour sampling at Day -1 and at Week 2 or Week 4 visit in a subset of patients | Day -1 and Week 2 or 4 visit (8 hour-sampling) | No |
Secondary | The levels of immune- and inflammation-related parameters in plasma as a measure of PD | To characterize the pharmacodynamics (PD) of GLPG0634 by measuring the levels of immune- and inflammation-related parameters in plasma | Day -1, Week 1, week 2 and week 4 visits | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |